There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for Johnson & Johnson (JNJ) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.71, or -0.42%, to $167.60. The Johnson & Johnson has recorded 380,039 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Johnson & Johnson Reports Q4 and Full-Year 2022 Results.
As a NYSE listed company, JNJ falls under the Healthcare sector while operating within the Drug Manufacturers – General industry segment. At the end of the last regular session, the stock closed at $168.31 and fluctuated between $175.00 as its day high and $166.01 as its day low. The current market capitalization of Johnson & Johnson is $442.10B. A total of 10.52 million shares were traded on the day, compared to an average of 6.47M shares.
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, JNJ has seen 11 BUY and 10 SELL insider trades, representing the acquisition of 260,566 and the disposition of 237,543 shares. Over the last 12 months, there were 46 BUYs and 370 SELLs from insiders. Insiders purchased 793,020 shares during that period but sold 627,781.
In the most recent transaction, Wolk Joseph J sold 14,781 shares of JNJ for 179.60 per share on Dec 13. After the transaction, the Exec VP, CFO now owns 35,812 company shares. In a previous transaction on Nov 30, McEvoy Ashley sold 73,323 shares at 175.47 per share. JNJ shares that EVP, WW Chair, MedTech owns now total 41,813.
Among the insiders who sold shares, Taubert Jennifer L disposed of 76,923 shares on Nov 22 at a per-share price of $176.78. This resulted in the EVP, WW Chair, Pharmaceuticals holding 126,456 shares of JNJ after the transaction. In another insider transaction, Decker Robert J sold 16,928 shares at $175.00 per share on Nov 18. Company shares held by the Controller, CAO now total 15,473.
Investors prefer companies that pay dividends because dividends generate immediate cash flow and indicate a positive outlook. Johnson & Johnson pays an annual dividend of $4.52, resulting in a dividend yield of 2.69%, and it has a price to earnings (P/E) ratio of 23.43. JNJ’s most recent ex-dividend date was 2/17/2023 when it declared a $1.13 quarterly dividend that was paid in cash on 3/7/2023. Previously, the company paid the dividend on 12/6/2022 with an ex-dividend date of 11/21/2022. The JNJ stock dividend was $1.13 per share in cash.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for JNJ in the last 3 months, the mean price target is $184.72 with high estimates of $215.00 and low estimates of $160.00. In terms of 52-week highs and lows, JNJ has a high of $186.69 and a low of $155.72.
As of this writing, JNJ has an earnings estimate of $2.23 per share for the current quarter. EPS was calculated based on a consensus of 15 estimates, with a high estimate of $2.25 per share and a lower estimate of $2.21. The company reported an EPS of $2.59 in the last quarter, which was 2.40% higher than expectations of $2.53.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 19 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for JNJ is Underweight with a score of 3.88. A total of 5 analysts rated the stock as Buy while 2 rated it as Overweight while 12 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.